Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: Response and relapse rates, and factors related to durability of HBeAg seroconversion

Intervirology

Volumn 48, Issue 6, 2005, Pages 341-349

  Seung, Kew Yoon ^a,b   Jeong, Won Jang ^a   Chang, Wook Kim ^a   Si, Hyun Bae ^a   Jong, Young Choi ^a   Sang, Wook Choi ^a   Young, Sok Lee ^a   Chang, Don Lee ^a   Kyu, Won Chung ^a   Hee, Sik Sun ^a   Boo, Sung Kim ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Antiviral response; Chronic hepatitis B; HBeAg seroconversion; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KOREA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KOREA; LAMIVUDINE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 22344438967     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086061     Document Type: Article

References (35)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thia-cytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
2. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
4. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
5. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; On behalf of the Asia Hepatitis Lamivudine Study Group: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
6. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
7. Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H: Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: Emergence of YMDD motif mutant and risk of breakthrough hepatitis - An open-cohort study. J Hepatol 2003;38:91-97.
8. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, Wong DK, Sum SM, Ng IO, Fan ST, Lai CL: Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003;39:850-855.
9. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
10. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH: Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212.
11. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS: Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37:669-674.
12. Schiff E, Cianciara J, Karayalcin S, Kowdley K, Woessner M. McMullen S, PearceM, Brown N, the International Lamivudine Investigator Group: Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (abstract). J Hepatol 2000;32(suppl 2):99.
13. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF: Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-1273.
14. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL: Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-534.
15. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, Ahn YO, Shigemastu T: Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: A case-control study in Pusan, Korea. Int J Epidemiol 1996;25:933-940.
16. Rho HM, Kim K, Hyun SW, Kim YS: The nucleotide sequence and reading frames of a mutant hepatitis B virus subtype adr. Nucleic Acids Res 1989;17:2124.
17. Kato H, Ruzibakiev R, Yuldasheva N, Hegay T, Kurbanov F, Achundjanov B, Tuichiev L, Usuda S, Ueda R, Mizokami M: Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. J Med Virol 2002;67:477-483.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
19. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N: Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30: 1082-1087.
20. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755.
21. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-763.
22. Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-774.
23. Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, Wong BC, Lai CL: A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: Implications for antiviral therapy. Gut 2003;52:416-419.
24. Guan R, Lai CL, Leung NWY, Lim SG, Lee CM, Ng KY, Chang TT, Nicholls GJ, Dent JC: Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstract). J Gastroenterol Hepatol 2001:16(suppl):A60.
25. Magnius LO, Norder H: Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
26. Ding X, Mizokami M, Yao G, Xu B, Orito E, Ueda R, Nakanishi M: Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 2001;44:43-47.
27. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001;34:590-594.
28. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH: Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
29. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
30. Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S, Koike K: Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 2001;120:1564-1565.
31. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
32. Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
33. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P: Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
34. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH: Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
35. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F: Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000;32:307-316.